



## Multidisciplinary Management of Rare Head and Neck Tumors: The Importance of Knowing and Dealing with Them

Guest Editor:

### Dr. Francesco Perri

Istituto Nazionale Tumori di  
Napoli, IRCCS “G. Pascale”, Via  
Mariano Semmola, 80131 Napoli,  
Italy

Deadline for manuscript  
submissions:  
**closed (31 March 2026)**

### Message from the Guest Editor

Dear Colleagues,

In recent years, advancements in molecular profiling and genomic characterization have provided invaluable insights into the underlying biology of rare head and neck cancers, unravelling novel therapeutic targets and paving the way for precision medicine approaches; however, significant gaps persist in our understanding of these malignancies, hindering progress towards improved outcomes. Through a meticulous review of the existing literature, coupled with insights gleaned from clinical practice and translational research, we endeavor to elucidate the etiopathogenesis, clinical characteristics, diagnostic modalities, treatment strategies, and prognostic factors pertaining to these malignancies.

Dr. Francesco Perri  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI